The Next Challenge in Hemophilia Care – EHC
European Haemophilia Consortium (EHC) shared CRH French Reference Center for Hemophilia Lyon’s post on LinkedIn:
“In the era of near-zero bleeds, success in haemophilia can no longer be measured by annualised bleeding rate (ABR) alone.
This new article by patient representative Nicolas Giraud (Association française des hémophiles (AFH) — EHC French National Member Organisation) and Prof Yesim Dargaud (CRH French Reference Center for Hemophilia Lyon) argues that haemostatic control is not synonymous with health.
Zero ABR doesn’t undo prior joint damage, restore function, or guarantee autonomy and quality of life.
And this reframing matters even more for the parts of our community that ‘near-zero bleeds’ doesn’t yet reach.
As the authors point out, ABR-based metrics were never built to capture menstrual bleeding — for women and girls, ‘zero bleeds’ isn’t even the relevant target, let alone an achievable one.
Comprehensive, patient-centred care has to mean something broader than a single number.”
CRH French Reference Center for Hemophilia Lyon shared a post on LinkedIn about a recent article by Nicolas Giraud and Yesim Dargaud, published in Hemophilia, adding:
“One patient. One physician. One shared conviction.
In the era of near-zero bleeds, success in hemophilia can no longer be measured by ABR alone.
Therapeutic innovation has transformed hemostatic control.
But are we translating these remarkable advances into better joint health, function, autonomy, quality of life, and meaningful participation?
In this article, a patient representative and a hematologist bring their perspectives together — and agree on one key message:
The next challenge in hemophilia care is not to redefine comprehensive care, but to make it a reality for every patient, in everyday clinical practice.
From controlling bleeding to enabling people to live well, move freely, participate fully, and achieve what matters to them.”
Title: From Bleeding Control to Health: Implementing Multidimensional and Multidisciplinary Hemophilia Care Into the Era of Therapeutic Innovation
Authors: Nicolas Giraud, Yesim Dargaud
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC